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Abstract  
 Diabetes type 2 is associated with other diseases including 
cardiovascular diseases. Obesity is a link between diabetes and 
cardiovascular diseases and associated with insulin resistance. Statins are 
used to reduce lipids and to lower the risk of cardiovascular diseases. The 
objective of the present study was to explore the effect of statin treatment on 
plasma levels of ICAM among diabetics. The study design was a prospective 
cohort clinical study. The study included 62 diabetic patients who were 
recruited from the Diabetes/Endocrine Clinics of the Prince Rashed Hospital. 
Data were collected from participants through a prepared questionnaire and 
laboratory findings of lipid profiles, glucose and ICAM levels. Study 
findings showed no significant variations between study and control groups 
at baseline level. At the end of the experiment, in study group, there were 
significant changes in some biochemical parameters such as ICAM level 
(p=0.005), cholesterol (0.019), and TG (0.025). The mean difference of 
study and control groups showed that significant variations were observed 
for the following variables ICAM (p<0.005), cholesterol (p=0.008), TG 
(p<0.005), and HDDL (p<0.005). Taken together, the present study showed 
that simvastatin therapy benefits diabetic patients even without 
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hyperlipidemia through decreasing levels of ICAM-1, which have an 
inflammatory action and increase insulin resistance. It can be concluded that 
simvastatin is insulin sensitizer and works as anti-inflammatory agent. 
 
Keywords: Diabetes type 2, ICAM, insulin resistance, statins, 
cardiovascular disease,  simvastatin 
 
Introduction  
 Insulin resistance is a factor that leads to type 2 diabetes and 
unfavourable cardiovascular consequences (Vettor et al., 2005; 
Semenkovich, 2006). Adipose tissues (white type) secrete a lot of adipokines 
and cytokines (protein signals) (Antuna-Puente et al., 2008; Qasim et al., 
2008) which play a role in insulin sensitivity, insulin resistance , blood 
pressure , energy balance,  angiogenesis and others (Endres, 2005; 
Kostapanos, Milionis, and Elisaf, 2008; Pantsulaia et al., 2009). 
 Patients with type 2 diabetes have a greater potential for the 
development of coronary heart diseases and atherosclerosis, in addition to 
the development of microvascular complications such as retinopathy, 
nephropathy and neuropathy due to endothelial dysfunction. Recent data 
showed that statins have a lot of benefits for decreasing these risks (Tekin et 
al., 2006). 
 Statins are used as lipid lowering agents, and they mediate their 
effects through the inhibition of the 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG-CoA) enzyme through the hepatic cholesterol biosynthesis 
pathway (Sotomayor et al., 2005; Naples et al., 2008; Shyu et al., 2009). 
Statins have been found to significantly lower lipids in patients with 
dyslipidaemia, and thereby reduce the risk of cardiovascular disease and 
atherosclerosis, in addition to improve insulin sensitivity and decrease the 
morbidity and mortality rates in patients with or without cardiovascular 
disease (Güçlü et al., 2004; Huptas et al., 2006; Lalli et al., 2008).  
 It is plausible that statins decrease inflammation through lowering 
levels of IL-6 and CRP which are inflammatory markers and consecutively 
reduce insulin resistance. However, these drugs also may influence the levels 
of other adipocytokines (adiponectin, resistin) (Antuna-Puente et al., 2008). 
 Inflammation is a physiological status that occurs as a response to 
tissue injury. Inflammation is categorized into two classes: acute and 
chronic. Acute inflammation has the following characteristics:  swelling, 
redness, heat, pain and loss in function. These signs occur due to 
physiological alterations of vasodilatation, increased vascular permeability 
and induction of nerve terminals. Chronic inflammation includes tissue 
damage and wound healing. These inflammatory classifications are differing 
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in the primary active immune cells that are involved in the inflammatory 
response (Pickup, 2004). 
 Expression of endothelial cell adhesion molecules is a marker for 
endothelial cell activation, and elevated expression is an indication of 
endothelial dysfunction. Increased soluble endothelial adhesion molecules in 
the plasma are markers of endothelial dysfunction and inflammation. At 
normal conditions, endothelial cells enhance expression of adhesion 
molecules E-selectin, vascular cell adhesion molecule (VCAM)-1 and 
intercellular adhesion molecule (ICAM)-1 to control leukocyte with 
endothelial cell interaction during the inflammatory response. Studies 
showed increased circulating levels of E-selectin, VCAM-1 and ICAM-1 in 
type 2 diabetics (Albertini et al., 1998; Matsumoto et al., 2002; Hamdy, 
Suwailem, and El-Mesallamy, 2009), which are considered predictors for 
type 2 diabetics (Thorand et al., 2006). Some studies found that the soluble 
form of ICAM-1 was not elevated in type 2 diabetics (Güler et al., 2002; 
Matsumoto et al., 2002), but suggested that elevated levels were indicative 
for developing of microvacsular complications, such as nephropathy (Güler 
et al., 2002). The suggested explanation for that is the soluble forms of 
ICAM-1 are found in the circulation in the later stages of diabetes, at the 
time that the risk of microvascular complications is much greater. Levels of 
E-selectin and VCAM-1 were accompanied with the degree of 
hyperglycemia and insulin sensitivity (Matsumoto et al., 2002). Also, 
oxidative stress has a role in the increased adhesion molecule expressions, 
and so chronic vitamin E intake for 3 months in type 2 diabetic individuals 
can decrease plasma ICAM-1 and VCAM-1 levels (Hamdy, Suwailem, and 
El-Mesallamy, 2009). 
 
Study objective 
 The main objective of the present study is to explore the effect of 
statin treatment on plasma levels of ICAM among diabetics.  
 
Materials and Methods 
Study Design 
 The study design was a prospective cohort clinical study. The 
approval of the Institutional review boards (IRB) of both Jordan University 
of Science and Technology, and King Abdullah University Hospital was 
obtained. In addition, the approval of the royal medical services for 
conducting the study at Military Prince Rashed Hospital was also obtained. 
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Study Setting   
 Sample recruitment was in 2011. Laboratory work; including 
biochemical analysis, ELISA was conducted. The study was conducted at 
healthcare facility in the north of Jordan; Military Prince Rashed Hospital. 
 
Sample Population 
Subject Description 
 The study included 62 diabetic patients who were recruited from the 
Diabetes/Endocrine Clinics of the Prince Rashed Hospital. 
 
Data Collection and Patient Interviews 
 A custom design questionnaire was utilized for appropriate data 
collection and further statistical analysis. The study procedure and goals 
were explained to patients both verbally and through the designed consent 
form. Patients who approved to participation-with total realization of 
confidentiality- signed the consent form, and were interviewed by the 
researcher using the designed questionnaire. Each patient’s medical profile 
of the diabetic clinic was reviewed for further collection and confirmation of 
patient’s demographics, clinical history and current drug regimen.  
 
Sample Collection and Handling 
 Blood samples were withdrawn from the participants after an 
overnight fasting by a specialized laboratory technician.Each sample was 
distributed in an evacuated EDTA tube (5 mL blood) as well as an 
anticoagulant-free plain tube (10 mL blood). The later were centrifuged at 
4000 rpm for 4 minutes. Five hundred micro liters of each serum sample 
were sent for biochemical analysis.  
 
Statistical Analysis 
 Data were analysed using SPSS version 17. Frequencies means and 
standard deviations were used to describe data wherever appropriate. Chi-
square test and T- test were used to test the difference between proportions. P 
–value of < 0.05 was considered statistically significant.  
 
Study findings 
General characteristics of study participants 
 As shown in table 1, there is a comparison between study and control 
groups at baseline with their statistical significance (p value < 0.05). Several 
parameters were investigated. Age, BMI, gender, family history of 
cardiovascular diseases, family history of thyroid disorders, family history of 
diabetes, heart diseases, and dyslipidemia were not varied significantly 
between study and control groups at baseline (p value > 0.05). 
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Table 1: General characteristics of study participants 
P value Control  group 
Mean  +/- SD or % 
Study group 
Mean +/- SD or % 
Variable 
0.516 57.06 +/- 10.27 55.34 +/- 13.54 Age 
0.261 35.71 +/- 29.62 29.36 +/- 5.07 BMI 
 
0.317 
 
14 (48.3%) 
15 (51.7%) 
 
19 (57.6%) 
14 (42.4%) 
Gender 
Male 
Female 
0.136 3 (10.3) 8 (24.2%) FHCD 
0.282 5 (17.2) 3 (9.1%) FHTD 
0.184 17 (56.6%) 24 (72.7%) FHDM 
0.144 3 (9.1%) 0 (0%) HD 
0.174 22 (66.7%) 15 (51%) Dislipidemia 
 
Concentration of biochemical tests in study and control groups 
 As shown in table 2, after the end of experiment, in study group, 
there were significant changes in some biochemical parameters such as 
ICAM level (p=0.005), cholesterol (0.019), and TG (0.025).  No significant 
variations were observed for other biochemical parameters, and no 
significant variation was observed in control group. 
Table 2: Concentration of biochemical tests in study and control groups 
Control group Study group  
p-
value 
Mean After ± 
SD 
Mean Before± 
SD 
p-
value 
Mean After ± SD Mean Before± 
SD 
variable 
0.411 17648.69± 
10989.33070 
21008.62± 
16706.93922 
< 
0.005 
12398.98± 
8539.78707 
31056.03± 
11666.72394 
ICAM 
0.051 201.03 ± 81.89 245.86 ± 94.187 0.571 221.87 ± 82.36 232.75 ±76.87 Glucose 
0.890 215.7241±43.522 214.2414±47.2407 0.019 201.9091±53.65070 220.7576±55.646 Cholesterol 
0.741 215.5862±110.29 225.4483±115.130 0.025 223.0303±178.6752 265.8182±210.41 TG 
0.853 44.6966±15.2369 45.2483±14.51141 0.302 47.5121±11.71038 44.7545±9.48641 HDL 
0.432 128.0345±36.882 120.0690±38.888 0.349 112.5152±37.82370 121.6364±42.011 LDL 
0.611 7.5 ±1.78 7.34 ±1.58 0.464 8.23 ±1.52 7.34 ±1.58 WBC 
0.785 88.59 ±12.67 93.95 ±11.21 0.431 92.60 ±63 79.96 ±49.86 Ck 
 
Comparison of the mean difference variation of biochemical markers 
between the study and control groups 
 We investigated the mean difference of study and control groups to 
show the magnitude of simvastatin therapeutic effects on study group in 
comparison with the control group. As shown in table 3, significant 
variations were observed for the following variables ICAM (p<0.005), 
cholesterol (p=0.008), TG (p<0.005), and HDDL (p<0.005). 
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Table 3: Comparison of the mean difference variation of biochemical markers between the 
study and control groups 
P–value Control group 
Mean difference 
Study group 
Mean difference 
variable 
< 0.005 -3359.931 -18657.06 ICAM 
0.008 1.4827 -18.8485 Cholesterol 
< 0.005 -9.8621 -42.7879 TG 
< 0.005 -0.5517 2.7576 HDL 
0.642 7.9655 -9.1212 LDL 
0.642 0.16 0.89 WBC 
0.415 -5.36 12.64 Ck 
 
Discussion 
 Our results showed that the level of ICAM  decreased significantly 
after treatment with simvastatin among study group in comparison with 
control group (p value <0.01) which indicates the magnitude of simvastatin 
therapy decreased the level of ICAM adipocytokine and this finding is 
consistent with other studies that showed increased circulating levels of 
ICAM in type 2 diabetics (Albertini et al., 1998; Matsumoto et al., 2002;  
Hamdy, Suwailem, and El-Mesallamy) and so decreased the microvascular 
complications in type 2 diabetic patients were elevated expression of ICAM 
is an indication of endothelial dysfunction and developing of microvacsular 
complications, such as nephropathy (Güler et al., 2002). 
 The results showed that the mean difference of study group in 
comparison with the mean difference of control group for glucose was 
statistically significant (p value <0.05) and this significance by decreasing 
the level of glucose among control group more than the decreasing among 
study group may be explained by the small number of participants and the 
short period of the study which not give a strong indication for strict glucose 
monitoring in this short period. 
 The results showed that the mean difference of study group was 
decreased by 18.84 mg/dl in comparison with the mean difference of control 
group which increased by 1.48 mg/dl for Cholesterol (p value 0.008) and this 
indicate the strong lipid lowering effect of simvastatin in decreasing 
cholesterol level. For TG the mean difference decreased by 42.78 mg/dl 
among study group and decreased by 9.86 mg/dl in control group (p value 
<0.01) which indicate also the beneficial effect of simvastatin in decreasing 
TG level .For  HDL the mean difference increased by 2.75 mg/dl among 
study group in comparison with decreased mean difference by 0.55 mg/dl 
among control group (p value <0.01) which revealed the beneficial effects of 
simvastatin in increasing the good cholesterol (HDL) in diabetic patients that 
decrease the atherosclerotic risks in these patients. LDL were significantly 
varied (p value < 0.032) between study and control groups were the mean 
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difference among study group  decreased by 9.12 mg/dl and increased  by 
7.96 mg/dl in control group which indicate the magnitude of simvastatin in 
decreasing the LDL level which has an important risk factor for 
atherosclerosis and macrovascular complications in type 2 diabetic patients. 
In view of these results, simvastatin has a strong action as a lipid lowering 
agent.        
 The results showed that the mean difference of study group in 
comparison with the mean difference of control group for WBC, Neutrophil 
count, and CK were not statistically significant (p value > 0.05 for the all). 
These findings can be viewed from different points among which no 
significant changes were identified before conducting the study regarding 
these variables. Another point represents a kinetic mode in which changes to 
be induced depend on a function of time or a large number of participants. 
Both of these factors are lacked in the present study. Taken together, the 
treatment of simvastatin induced several positive changes as enhancing 
insulin sensitivity, reducing inflammatory parameters and lipid lowering 
effect. 
 
Conclusion 
 The present study showed that simvastatin therapy benefits diabetic 
patients even without hyperlipidemia through decreasing levels of ICAM-1, 
which have an inflammatory action and increase insulin resistance. It can be 
concluded that simvastatin is insulin sensitizer and works as anti-
inflammatory agent. 
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